via The Scientist RSS https://ift.tt/3hnV6l5 The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases the risk for developing cardiovascular disease. https://ift.tt/uEtkhsX July 13, 2022 at 01:34AM